Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.

Blumenthal DT, Won M, Mehta MP, Gilbert MR, Brown PD, Bokstein F, Brachman DG, Werner-Wasik M, Hunter GK, Valeinis E, Hopkins K, Souhami L, Howard SP, Lieberman FS, Shrieve DC, Wendland MM, Robinson CG, Zhang P, Corn BW.

Neuro Oncol. 2018 Jun 18;20(7):966-974. doi: 10.1093/neuonc/noy017.

PMID:
29462493
2.

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.

Purim O, Beny A, Inbar M, Shulman K, Brenner B, Dudnik E, Bokstein F, Temper M, Limon D, Matceyevsky D, Sarid D, Segal A, Semenisty V, Brenner R, Peretz T, Idelevich E, Pelles-Avraham S, Meirovitz A, Figer A, Russell K, Voss A, Dvir A, Soussan-Gutman L, Hubert A.

Target Oncol. 2018 Apr;13(2):217-226. doi: 10.1007/s11523-017-0548-8.

3.

Neurologic complications of immune checkpoint inhibitors.

Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, Blumenthal DT, Mandel J, Fichman S, Kogan E, Steiner I, Siegal T, Lossos A, Yust-Katz S.

J Neurooncol. 2018 May;137(3):601-609. doi: 10.1007/s11060-018-2752-5. Epub 2018 Jan 13.

PMID:
29332184
4.

Differentiation between vasogenic edema and infiltrative tumor in patients with high-grade gliomas using texture patch-based analysis.

Artzi M, Liberman G, Blumenthal DT, Aizenstein O, Bokstein F, Ben Bashat D.

J Magn Reson Imaging. 2018 Jan 3. doi: 10.1002/jmri.25939. [Epub ahead of print]

PMID:
29314345
5.

MRI radiomics analysis of molecular alterations in low-grade gliomas.

Shofty B, Artzi M, Ben Bashat D, Liberman G, Haim O, Kashanian A, Bokstein F, Blumenthal DT, Ram Z, Shahar T.

Int J Comput Assist Radiol Surg. 2018 Apr;13(4):563-571. doi: 10.1007/s11548-017-1691-5. Epub 2017 Dec 21.

PMID:
29270916
6.

Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.

Blumenthal DT, Kanner AA, Aizenstein O, Cagnano E, Greenberg A, Hershkovitz D, Ram Z, Bokstein F.

World Neurosurg. 2018 Feb;110:e727-e737. doi: 10.1016/j.wneu.2017.11.105. Epub 2017 Nov 26.

PMID:
29183864
7.

Spinal and Paraspinal Plexiform Neurofibromas in Patients with Neurofibromatosis Type 1: A Novel Scoring System for Radiological-Clinical Correlation.

Mauda-Havakuk M, Shofty B, Ben-Shachar S, Ben-Sira L, Constantini S, Bokstein F.

AJNR Am J Neuroradiol. 2017 Oct;38(10):1869-1875. doi: 10.3174/ajnr.A5338. Epub 2017 Aug 10.

PMID:
28798215
8.

Cranial irradiation in childhood mimicking neurofibromatosis type II.

Bokstein F, Dubov T, Toledano-Alhadef H, Bernstein-Molho R, Constantini S, Evans DG, Ben-Shachar S.

Am J Med Genet A. 2017 Jun;173(6):1635-1639. doi: 10.1002/ajmg.a.38211. Epub 2017 Apr 19.

PMID:
28422417
9.

Classification of High-Grade Glioma into Tumor and Nontumor Components Using Support Vector Machine.

Blumenthal DT, Artzi M, Liberman G, Bokstein F, Aizenstein O, Ben Bashat D.

AJNR Am J Neuroradiol. 2017 May;38(5):908-914. doi: 10.3174/ajnr.A5127. Epub 2017 Apr 6.

10.

Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study.

Artzi M, Liberman G, Vaisman N, Bokstein F, Vitinshtein F, Aizenstein O, Ben Bashat D.

J Neurooncol. 2017 Apr;132(2):267-275. doi: 10.1007/s11060-016-2364-x. Epub 2017 Jan 10.

PMID:
28074323
11.

NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.

Gilbert MR, Pugh SL, Aldape K, Sorensen AG, Mikkelsen T, Penas-Prado M, Bokstein F, Kwok Y, Lee RJ, Mehta M.

J Neurooncol. 2017 Jan;131(1):193-199. doi: 10.1007/s11060-016-2288-5. Epub 2016 Oct 21.

12.

Mechanisms of post-radiation injury: cerebral microinfarction not a significant factor.

Molad JA, Blumenthal DT, Bokstein F, Findler M, Finkel I, Bornstein NM, Yust-Katz S, Auriel E.

J Neurooncol. 2017 Jan;131(2):277-281. doi: 10.1007/s11060-016-2291-x. Epub 2016 Oct 18.

PMID:
27757722
13.

Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.

Blumenthal DT, Dvir A, Lossos A, Tzuk-Shina T, Lior T, Limon D, Yust-Katz S, Lokiec A, Ram Z, Ross JS, Ali SM, Yair R, Soussan-Gutman L, Bokstein F.

J Neurooncol. 2016 Oct;130(1):211-219. Epub 2016 Aug 16.

PMID:
27531351
14.

The effect of parental age on the presence of de novo mutations - Lessons from neurofibromatosis type I.

Dubov T, Toledano-Alhadef H, Bokstein F, Constantini S, Ben-Shachar S.

Mol Genet Genomic Med. 2016 Jun 16;4(4):480-6. doi: 10.1002/mgg3.222. eCollection 2016 Jul.

15.

Optimization of DCE-MRI protocol for the assessment of patients with brain tumors.

Artzi M, Liberman G, Nadav G, Blumenthal DT, Bokstein F, Aizenstein O, Ben Bashat D.

Magn Reson Imaging. 2016 Nov;34(9):1242-1247. doi: 10.1016/j.mri.2016.07.003. Epub 2016 Jul 21.

PMID:
27451404
16.

Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas.

Daniels D, Guez D, Last D, Hoffmann C, Nass D, Talianski A, Tsarfaty G, Salomon S, Kanner AA, Blumenthal DT, Bokstein F, Harnof S, Yekutieli D, Zamir S, Cohen ZR, Zach L, Mardor Y.

AJNR Am J Neuroradiol. 2016 Jul 7. [Epub ahead of print]

PMID:
27390321
17.

Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors.

Blumenthal DT, Yalon M, Vainer GW, Lossos A, Yust S, Tzach L, Cagnano E, Limon D, Bokstein F.

J Neurooncol. 2016 Sep;129(3):453-460. doi: 10.1007/s11060-016-2190-1. Epub 2016 Jul 4.

PMID:
27377654
18.

Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.

Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP.

J Clin Oncol. 2016 May 10;34(14):1620-5. doi: 10.1200/JCO.2015.64.8634. Epub 2016 Mar 28.

19.

Erratum to: The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?

Blumenthal DT, Mendel L, Bokstein F.

J Neurooncol. 2016 May;127(3):503. doi: 10.1007/s11060-016-2100-6. No abstract available.

PMID:
26956262
20.

Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI.

Artzi M, Liberman G, Nadav G, Blumenthal DT, Bokstein F, Aizenstein O, Ben Bashat D.

J Neurooncol. 2016 May;127(3):515-24. doi: 10.1007/s11060-016-2055-7. Epub 2016 Jan 11.

PMID:
26754857
21.

The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?

Blumenthal DT, Mendel L, Bokstein F.

J Neurooncol. 2016 May;127(3):493-502. doi: 10.1007/s11060-015-2025-5. Epub 2015 Dec 31. Erratum in: J Neurooncol. 2016 May;127(3):503.

PMID:
26721244
22.

Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results.

Bokstein F, Blumenthal DT, Corn BW, Gez E, Matceyevsky D, Shtraus N, Ram Z, Kanner AA.

J Neurooncol. 2016 Feb;126(3):551-7. doi: 10.1007/s11060-015-1997-5. Epub 2015 Nov 24.

PMID:
26603164
23.

Calcification in high grade gliomas treated with bevacizumab.

Blumenthal DT, Aisenstein O, Ben-Horin I, Ben Bashat D, Artzi M, Corn BW, Kanner AA, Ram Z, Bokstein F.

J Neurooncol. 2015 Jun;123(2):283-8. doi: 10.1007/s11060-015-1796-z. Epub 2015 May 5.

PMID:
25939440
24.

Human cerebral blood volume measurements using dynamic contrast enhancement in comparison to dynamic susceptibility contrast MRI.

Artzi M, Liberman G, Nadav G, Vitinshtein F, Blumenthal DT, Bokstein F, Aizenstein O, Ben Bashat D.

Neuroradiology. 2015 Jul;57(7):671-8. doi: 10.1007/s00234-015-1518-4. Epub 2015 Apr 7.

PMID:
25845809
25.

Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.

Ellingson BM, Kim E, Woodworth DC, Marques H, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Int J Oncol. 2015 May;46(5):1883-92. doi: 10.3892/ijo.2015.2891. Epub 2015 Feb 11.

26.

Monitoring brain tumor vascular heamodynamic following anti-angiogenic therapy with advanced magnetic resonance imaging in mice.

Laufer S, Mazuz A, Nachmansson N, Fellig Y, Corn BW, Bokstein F, Bashat DB, Abramovitch R.

PLoS One. 2014 Dec 15;9(12):e115093. doi: 10.1371/journal.pone.0115093. eCollection 2014.

27.

Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma.

Artzi M, Blumenthal DT, Bokstein F, Nadav G, Liberman G, Aizenstein O, Ben Bashat D.

J Neurooncol. 2015 Jan;121(2):349-57. doi: 10.1007/s11060-014-1639-3. Epub 2014 Nov 5.

PMID:
25370705
28.

Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.

Artzi M, Bokstein F, Blumenthal DT, Aizenstein O, Liberman G, Corn BW, Ben Bashat D.

Eur J Radiol. 2014 Jul;83(7):1250-1256. doi: 10.1016/j.ejrad.2014.03.026. Epub 2014 Apr 12.

PMID:
24809637
29.

Optic pathway gliomas in adults.

Shofty B, Constantini S, Bokstein F, Ram Z, Ben-Sira L, Freedman S, Vainer G, Kesler A.

Neurosurgery. 2014 Mar;74(3):273-9; discussion 279-80. doi: 10.1227/NEU.0000000000000257.

PMID:
24335817
30.

Gliomas of the posterior fossa in adults.

Strauss I, Jonas-Kimchi T, Bokstein F, Blumenthal D, Roth J, Sitt R, Wilson J, Ram Z.

J Neurooncol. 2013 Dec;115(3):401-9. doi: 10.1007/s11060-013-1231-2. Epub 2013 Aug 27.

PMID:
23979683
31.

Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.

Ratai EM, Zhang Z, Snyder BS, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Gilbert MR, Sorensen AG, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):936-44. doi: 10.1093/neuonc/not044. Epub 2013 May 3.

32.

Hemodynamic response imaging: a potential tool for the assessment of angiogenesis in brain tumors.

Ben Bashat D, Artzi M, Ben Ami H, Aizenstein O, Blumenthal DT, Bokstein F, Corn BW, Ram Z, Kanner AA, Lifschitz-Mercer B, Solar I, Kolatt T, Palmon M, Edrei Y, Abramovitch R.

PLoS One. 2012;7(11):e49416. doi: 10.1371/journal.pone.0049416. Epub 2012 Nov 27.

33.

Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma.

Liberman G, Louzoun Y, Aizenstein O, Blumenthal DT, Bokstein F, Palmon M, Corn BW, Ben Bashat D.

Eur J Radiol. 2013 Feb;82(2):e87-94. doi: 10.1016/j.ejrad.2012.09.001. Epub 2012 Sep 25.

PMID:
23017192
34.

The impact of enrollment in clinical trials on survival of patients with glioblastoma.

Shahar T, Nossek E, Steinberg DM, Rozovski U, Blumenthal DT, Bokstein F, Sitt R, Freedman S, Corn BW, Kanner AA, Ram Z.

J Clin Neurosci. 2012 Nov;19(11):1530-4. doi: 10.1016/j.jocn.2012.04.005. Epub 2012 Sep 16.

PMID:
22989795
35.

Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line?

Lawrence YR, Blumenthal DT, Matceyevsky D, Kanner AA, Bokstein F, Corn BW.

J Neurooncol. 2011 Oct;105(1):1-7. doi: 10.1007/s11060-011-0589-2. Epub 2011 Apr 24. Review.

PMID:
21516461
36.

Zoster sine herpete: virologic verification by detection of anti-VZV IgG antibody in CSF.

Blumenthal DT, Shacham-Shmueli E, Bokstein F, Schmid DS, Cohrs RJ, Nagel MA, Mahalingam R, Gilden D.

Neurology. 2011 Feb 1;76(5):484-5. doi: 10.1212/WNL.0b013e31820a0d28. No abstract available.

37.

Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.

Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T; International Primary CNS Lymphoma Collaborative Group.

Blood. 2010 Jun 17;115(24):5005-11. doi: 10.1182/blood-2009-12-258210. Epub 2010 Apr 5.

38.

Antiangiogenesis in recurrent glioblastoma: proof of principle.

Nossek E, Ram Z, Bokstein F, Blumenthal D.

Neurol Int. 2009 Nov 16;1(1):e21. doi: 10.4081/ni.2009.e21.

39.

A common sense approach to radiotherapy planning of glioblastoma multiforme situated in the temporal lobe.

Bokstein F, Kovner F, Blumenthal DT, Ram Z, Templehoff H, Kanner AA, Corn BW.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):900-4. doi: 10.1016/j.ijrobp.2008.01.053. Epub 2008 Apr 11.

PMID:
18407432
40.

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.

Bokstein F, Shpigel S, Blumenthal DT.

Cancer. 2008 May 15;112(10):2267-73. doi: 10.1002/cncr.23401.

41.

Surgical therapies in brain metastasis.

Kanner AA, Bokstein F, Blumenthal DT, Ram Z.

Semin Oncol. 2007 Jun;34(3):197-205. Review.

PMID:
17560981
42.

Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.

Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T.

J Neurooncol. 2006 Sep;79(2):153-7. Epub 2006 Jul 20.

PMID:
16855865
43.
44.

Assessment of neurolymphomatosis by brachial plexus biopsy and PET/CT. Report of a case.

Bokstein F, Goor O, Shihman B, Rochkind S, Even-Sapir E, Metser U, Neufeld M.

J Neurooncol. 2005 Apr;72(2):163-7.

PMID:
15925997
45.

Radiotherapy for spinal cord compression in patients with soft-tissue sarcoma.

Merimsky O, Kollender Y, Bokstein F, Issakov J, Flusser G, Inbar MJ, Meller I, Bickels J.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1468-73.

PMID:
15050325
46.

Malignant involvement of the spine: assessment by 18F-FDG PET/CT.

Metser U, Lerman H, Blank A, Lievshitz G, Bokstein F, Even-Sapir E.

J Nucl Med. 2004 Feb;45(2):279-84.

47.

Does streaming affect the cerebral distribution of infraophthalmic intracarotid chemotherapy?

Agid R, Rubinstein R, Siegal T, Lester H, Bokstein F, Chisin R, Gomori JM.

AJNR Am J Neuroradiol. 2002 Nov-Dec;23(10):1732-5.

48.
49.

Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.

Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T.

Clin Pharmacol Ther. 2000 Jun;67(6):631-41.

PMID:
10872645
50.

In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.

Siegal T, Rubinstein R, Bokstein F, Schwartz A, Lossos A, Shalom E, Chisin R, Gomori JM.

J Neurosurg. 2000 Apr;92(4):599-605.

PMID:
10761648

Supplemental Content

Loading ...
Support Center